We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.10 | 9.70 | 10.50 | 10.10 | 9.975 | 10.10 | 211,828 | 08:00:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.83 | 93.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/9/2023 13:06 | or the existing news incorrectly valued ? | inanaco | |
18/9/2023 13:02 | Up 38% on what. Must be expecting big news at the US Cancer presentation - but what isn't it all data /news that is already out there? | octopus100 | |
18/9/2023 12:48 | Bermuda has been quite today ... watching from a distance | inanaco | |
18/9/2023 12:41 | standard of care ........ Immunotherapy Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer. The following types of immunotherapy are being used in the treatment of melanoma: Immune checkpoint inhibitor therapy: Immune checkpoint inhibitors block proteins called checkpoints that are made by some types of immune system cells, such as T cells, and some cancer cells. These checkpoints help keep immune responses from being too strong and sometimes can keep T cells from killing cancer cells. When these checkpoints are blocked, T cells can kill cancer cells better. They are used to treat some patients with advanced melanoma or tumors that cannot be removed by surgery. There are two types of immune checkpoint inhibitor therapy: Pd-1 and CTL4 the Scope trial is showing efficacy above standard of care so it becomes Very commercial and what you don't realise every other checkpoint will need to trial with Iscib1 if the triplet treatment works that would also apply to synergy with Modi1 | inanaco | |
18/9/2023 12:37 | Tempted to add to position. | red army | |
18/9/2023 12:32 | we are scratching the surface ......... and as yet we had not deployed a t cell enhancer mab2811 | inanaco | |
18/9/2023 12:30 | there is no direct conflict between the t cells as they are a different class the immunobody t cells will respond to the cytokines given off by modi | inanaco | |
18/9/2023 12:29 | in otherwords if patients slip the net ...... treat with moditope as well if modi is proven safe and works with a checkpoint ..... it will be safe with an immunobody | inanaco | |
18/9/2023 12:26 | It will be recalled that the ImmunoBody® platform induces a high avidity CD8+ T cell response to tumour associated antigens. As the Moditope® platform stimulates a potent CD4+ T cell response to modified self-antigens both platforms are complementary relying on a response by different classes of T cell for their therapeutic effect. Thus, in principle, a combination of ImmunoBody® and Moditope® derived therapeutics may be a powerful approach to the treatment of both early and late stage cancers. | inanaco | |
18/9/2023 12:18 | always worth a read | inanaco | |
18/9/2023 12:16 | From antibody studies, vimentin expressed in all of the following tumour types: Breast Prostate Ovarian Cervical Endometrial Head and neck Thyroid Glioma Lung Melanoma Skin Testis Urothelial Renal Stomach Pancreatic Liver | inanaco | |
18/9/2023 12:14 | Now Number 3 on the Leaderboard Up 38.6% at 14p on volume of 3.4 million. Just reversed the completely unjustified fall from this level at the end of June. This has a lot farther to go as we await RNS news, just remember we went above 20p in April this year in anticipation of news. | 888icb | |
18/9/2023 12:12 | While we are waiting for the Modi Scib and Glymab data a reminder of what Trinity thinks the platforms could be worth. I think they are a little low on Moditope because we have Modi-2, 3 coming down the line. Moditope peak sales £3.5 billion, royalties 17.5% Immunobody " " £2.5 billion, " " Glymabs " " £5 billion " " Avidimab " " £8.5 billion " 8% | marcusl2 | |
18/9/2023 12:04 | Crazy mcap | wewillwin20 | |
18/9/2023 12:03 | .......it is the arrival of the "informed investors", taking stock off the uninformed, who have formed the market recently. | markingtime | |
18/9/2023 12:01 | Must be more to this. Still possible it's just a large investor building a stake but feels like something behind the scenes. | nigelpm | |
18/9/2023 11:59 | Will dump soon | firestarter1 | |
18/9/2023 11:50 | ....no need, charlatan.Stick to chopping your wood.... | markingtime | |
18/9/2023 11:44 | GUFFAW - You will learn | the real lozan | |
18/9/2023 11:39 | I mean you, chum.....:-) | markingtime | |
18/9/2023 11:38 | Clearly = EGOboy ... "Those who seek to mislead others about what they said (and when) just love to remain ambiguous by obfuscating (ie. what some of us would term "lying" :'-))" . Couldn't have put it better myself | the real lozan | |
18/9/2023 11:31 | So that's a "no" then........Those who seek to mislead others about what they said (and when) just love to remain ambiguous by obfuscating (ie. what some of us would term "lying" :'-)) | markingtime | |
18/9/2023 11:00 | The Kept Mans Diary .... accounts signed off by Colin () does not mean a loss 2+2=5 ..... a result with a tolerance + or - 1 | inanaco | |
18/9/2023 10:52 | An oft repeated error here = "Just for the record," 2 + 2 = 5 Common practice here to speak of things that are not known EGOboy is well versed in 2 + 2 = 5...( or even 8+ ) | the real lozan | |
18/9/2023 10:43 | .....ie....12.5p | markingtime |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions